IDEXX Laboratories Launches New SNAP® Giardia Test

"Studies have shown that Giardia is highly prevalent in dogs and cats, therefore it is in the best interest of the patient and client to quickly identify and treat infection," said Dr. Leif Lorentzen of IDEXX. "Until now, a fecal float evaluation or a fecal smear provided the only options for screening Giardia in-house, and their accuracy is very low. Typically, a fecal float identifies only half of infected dogs and falsely diagnoses up to 25% of uninfected patients. The new USDA-approved SNAP® Giardia Test is proven to deliver 95% sensitivity/99.3% specificity compared to IFA, and 96.2% sensitivity/100% specificity compared to reference laboratory ELISA tests."

The IDEXX SNAP® Giardia Test uses gold-standard ELISA technology, trusted by thousands of veterinarians for accuracy and ease-of-use. This test procedure includes a unique conjugate fecal swab that allows for much easier, "hands-off" sampling.

To order the new 15-test kits, please contact your authorized IDEXX distributor or call IDEXX at 1-800-248-2483.

IDEXX Laboratories, Inc., is a worldwide leader in the development and commercialization of innovative, technology-based products and services for animal health. The Company's largest business is focused on companion animal health, combining biotechnology, medical device technology and information technology to aid veterinarians in providing better medicine while building successful practices. IDEXX Laboratories is also focused on employing innovative technologies to monitor production animal health and the safety and quality of drinking water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs over 2,400 people and offers products to customers in more than 100 countries.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations of future events, which are subject to risks and uncertainties. If underlying assumptions prove inaccurate, actual results could vary materially from management's expectations. Risks and uncertainties include timing and success of new product introductions, competition and technological change, government regulation and obtaining government approvals, product demand and market acceptance, availability of products and raw materials, and litigation. A further description of these risks and uncertainties and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2002 (PDF, 350 KB) and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2003 (PDF, 2,277 KB), in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations." The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.